A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT03313960
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT03313960
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT03313960. Randomized; no masking; primary purpose treatment. Start 2017-10-05 (actual); primary completion 2018-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Afrezza plus One Drop | Premium
- Intervention (Other)
- One Drop | Premium
- Lead sponsor
- Informed Data Systems, Inc.
- Collaborator
- Mannkind Corporation
Record details
- Record id
cardio:ct-nct03313960- Content hash
97ca892720530c6fd02df09f6bc9efdedb161c6f633984a1ab4c9f5d6cbb71b4